Sutura Announces Key Sales Success.

FOUNTAIN VALLEY, Calif. -- Sutura, Inc. ("Sutura")(OTCBB:SUTU), a California-based medical device company, announced today that its U.S. sales team has introduced the SuperStitch vascular suturing device to 75 key medical facilities. These product demonstrations are the direct result of efforts by the Company's recently expanded SuperStitch sales force.

Anthony Nobles, President and Chief Executive Officer at Sutura, Inc. stated, "Introducing the SuperStitch to these key medical facilities is a significant milestone for Sutura. Among these facilities are some of the top medical institutions, universities, training facilities and cardiology centers. The newly formed sales team has spent the past three months targeting key institutions and has made significant inroads, which the Company believes will lead to increased penetration of this market. We now believe we are in a strong position to roll out the SuperStitch to the full medical community over the next several months."

"As these introductions and evaluations conclude, we are seeing more and more conversions to Sutura's SuperStitch device," says Tom Lindsey, Vice President Sales and Marketing at Sutura. "These new customers are telling us that our vascular suturing device is performing to the high level expected in the Cath Lab and we believe this will lead to increased sales of the product as we expand our sales efforts to additional facilities."

About Sutura, Inc.

Sutura(R), Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.

Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura(R)" and "SuperStitch(R)" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch(R) devices by medical providers and the marketplace in general and the success of the proposed sales and marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Sutura, Inc. (OTC Bulletin Board:SUTU)